| Date | Title | Description |
| 21.12.2025 | Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 | BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive dev... |
| 15.10.2025 | Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline | BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Eq... |
| 26.09.2025 | Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth | BEIJING, SHANGHAI and BOSTON, Sept. 26, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their ... |
| 30.08.2025 | Jacobio Pharma Announces 2025 Interim Results | BEIJING and SHANGHAI and BOSTON, Aug. 30, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025.
During the reporting period, the Company achieved revenue of RMB45.7 million... |
| 19.03.2025 | Jacobio Pharma Announces 2024 Annual Results | BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RM... |
| 07.01.2025 | The Registrational Clinical Data of Glecirasib was Published in Nature Medicine | BEIJING, SHANGHAI and BOSTON, Jan. 7, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently d... |
| 09.12.2024 | Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH | BEIJING, SHANGHAI and BOSTON, Dec. 9, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor J... |
| 30.08.2024 | Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China | BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong... |
| 02.06.2024 | Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO | BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combinatio... |
| 01.05.2024 | Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint | BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary ... |
| 22.03.2023 | Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer | BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclona... |
| 02.12.2022 | Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022 | BEIJING, SHANGHAI and BOSTON, Dec. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models in a... |
| 13.10.2022 | Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab | BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 a... |
| 02.09.2022 | Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China | BEIJING, Sept. 1, 2022 /PRNewswire/ -- JacobioPharma (1167.HK) announced that the company has dosed the first non-small cell lung cancer (NSCLC) patient with KRAS G12C and STK11 co-mutation in the Phase IIa trial of KRAS G12C inhibitor JAB-... |
| 24.08.2022 | Jacobio Pharma Announces 2022 Interim Results | Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million.
Global development of KRAS G12C inhibitor and other clinical stage drug candidates accelerated.
Development started in new pre-clinical stage d... |
| 28.05.2022 | Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting | BEIJING, SHANGHAI and BOSTON, May 28, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual m... |
| 31.08.2021 | Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy | |
| 31.08.2021 | Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy | BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell on August 31. Jacobio will collaborate with Hebe... |
| 18.06.2021 | Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment | BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 ... |
| 18.06.2021 | JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering $20 Million Milestone Payment | Jacobio Pharmaceuticals announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, thereby tr... |
| 17.06.2021 | Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment | |
| 03.05.2021 | Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor | BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company's Investigational New Drug (IND) application to develop a KRAS G12... |
| 29.03.2021 | Jacobio Pharmaceuticals : Pharma Announces CNY486 Million Revenue for 2020 Annual Results | BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its first annual results after its Hong Kong listing. By the end of December 31, 2020, its annual revenue was 486 million yuan and R&D expens... |
| 29.03.2021 | JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Jacobio Pharmaceuticals : Pharma Announces CNY486 Million Revenue for 2020 Annual Results | BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its first annual results after its Hong Kong listing. By the end of December 31, 2020, its annual revenue was 486 million yuan and R&D expens... |
| 29.03.2021 | Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results | |
| 03.09.2018 | China Digest: Jacobio Pharma secures $55m; BestSign raises $52.4m in Series C | Premium
Chinese startups Jacobio Pharmaceuticals and BestSign have raised $55 million and $52.4 million, respectively, from big-name investors.
Continue reading this story with a subscription to DealStreetAsia.
Subscribe
Already a subscribe... |
| 31.08.2018 | Qiming, Hillhouse lead Jacobio’s $55M series C | China’s Jacobio Pharmaceuticals has raised $55 million in series C funding to advance an oncology asset into the clinic, conduct preclinical work and ramp up its R&D pipelines.
Founded in 2015, Beijing-based Jacobio is working on drugs ... |
| 31.08.2018 | Qiming, Hillhouse bet on Jacobio's nascent pipeline of first-in-class drug hopefuls in $55M round | Qiming Capital and Hillhouse Capital are betting on a Chinese biotech to deliver world-class innovation in their latest investment.
Aside from the two prominent VCs, Jacobio has also attracted Hong Kong-based Prudence... |
| - | Qiming, Hillhouse lead Jacobio's $55M series C | - |
